Streptococcus pneumoniae: Virulence factor, pathogenesis, and two typical drugs with distinctive mechanism

Lifan Yue

doi:10.54254/2753-8818/45/20240524

Research Article

Open access

Published on 26 July 2024

Download pdf

Yue,L. (2024). Streptococcus pneumoniae: Virulence factor, pathogenesis, and two typical drugs with distinctive mechanism. Theoretical and Natural Science,45,122-129.

Export citation

Streptococcus pneumoniae: Virulence factor, pathogenesis, and two typical drugs with distinctive mechanism

Lifan Yue *^,1,

¹ University of Bristol

* Author to whom correspondence should be addressed.

https://doi.org/10.54254/2753-8818/45/20240524

Abstract

Streptococcus Pneumoniae is one of the major respiratory pathogens. It causes respiratory tract infection, Otitis media, meningitis, septicaemia, and other diseases, which can develop fast and become life-threatening in several days if left untreated. This gram-positive bacterium has toxic cell wall and secreted proteins, invading human body when the immune system is weak. One common treatment against S. Pneumoniae is through Augmentin, the combination of amoxicillin and clavulanic acid. The former is an β-lactam antibiotic, which kill the cells by binding to PBPs and arrest cell wall synthesis, while the latter is an β-lactamase inhibiter frequently combined with β-lactam antibiotics, as a countermeasure of developing antibiotic resistance. Another drug is Azithromycin, a macrolide antibiotic, works by binding the 50S subunit in the bacterial ribosome and partially blocks NPET, a channel for newly synthesized peptides to leave. The drugs in this family have a specificity on amino acid sequence, rather than simply block and stop translation thoroughly.

Keywords

Streptococcus Pneumoniae, Virulence Factors, Antibiotic Resistance, Augmentin, Azithromycin

View pdf

References

[1]. Cherazard, Regine MD1; Epstein, Marcia MD2; Doan, Thien-Ly PharmD3; Salim, Tanzila MBBS1; Bharti, Sheena DO2; Smith, Miriam A. MD, MBA1,*. Antimicrobial Resistant Streptococcus pneumoniae: Prevalence, Mechanisms, and Clinical Implications. American Journal of Therapeutics 24(3): p e361-e369, May 2017. | DOI: 10.1097/MJT.0000000000000551

[2]. atterall JR. Streptococcus pneumoniae Thorax 1999; 54:929-937. Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book) - 14th Edition (2021)

[3]. George RC. The epidemiology of pneumococcal disease. In: Mayon-White RT, ed. The clinical impact of pneumococcal disease and strategies for its prevention. London: Royal Society of Medicine, 1995: 1–7.

[4]. Gil E, Noursadeghi M, Brown JS. Streptococcus pneumoniae interactions with the complement system. Front Cell Infect Microbiol. 2022 Jul 28; 12:929483. doi: 10.3389/fcimb.2022.929483. PMID: 35967850; PMCID: PMC9366601.

[5]. Lima LM, Silva BNMD, Barbosa G, Barreiro EJ. β-lactam antibiotics: An overview from a medicinal chemistry perspective. Eur J Med Chem. 2020 Dec 15; 208:112829. doi: 10.1016/j.ejmech.2020.112829. Epub 2020 Sep 16. PMID: 33002736.

[6]. Heidary M, Ebrahimi Samangani A, Kargari A, Kiani Nejad A, Yashmi I, Motahar M, Taki E, Khoshnood S. Mechanism of action, resistance, synergism, and clinical implications of azithromycin. J Clin Lab Anal. 2022 Jun;36(6): e24427. doi: 10.1002/jcla.24427. Epub 2022 Apr 21. PMID: 35447019; PMCID: PMC9169196.

[7]. Ahmed H.H. Bakheit, Badraddin M.H. Al-Hadiya, Ahmed A. Abd-Elgalil, Chapter One -Azithromycin, Editor(s): Harry G. Brittain, Profiles of Drug Substances, Excipients and Related Methodology, Academic Press, Volume 39, 2014, Pages 1-40, ISSN 1871-5125, ISBN 9780128001738, https://doi.org/10.1016/B978-0-12-800173-8.00001-5.

Cite this article

Yue,L. (2024). Streptococcus pneumoniae: Virulence factor, pathogenesis, and two typical drugs with distinctive mechanism. Theoretical and Natural Science,45,122-129.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Volume title: Proceedings of the 2nd International Conference on Modern Medicine and Global Health

Conference website: https://www.icmmgh.org/

ISBN：978-1-83558-551-1(Print) / 978-1-83558-552-8(Online)

Conference date: 5 January 2024

Editor：Mohammed JK Bashir

Series: Theoretical and Natural Science

Volume number: Vol.45

ISSN：2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).